AgonOx

4 articles about AgonOx

• Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

  5/24/2023

  Phio Pharmaceuticals Corp. today announced its clinical development partner, AgonOx, Inc, in collaboration with Providence Cancer Institute, has completed the site initiation visit and can commence with patient accrual.

• Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies

  3/1/2021

  Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced it has entered into a clinical development collaboration with AgonOx, Inc.

• Daiichi Sankyo Announces New Strategic Immuno-Oncology Research Collaboration With AgonOx

  10/4/2016

• AgonOx’s OX40 Platform Being Utilized In MedImmune’s Phase 1 OX40 Agonist Study

  10/20/2014